Cybin Inc. (HELP) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Helus Pharma expects a Phase III readout for its deuterated psilocin program in adjunctive major depressive disorder in Q4 2026, creating a near-term clinical catalyst. The company is also finalizing the next-trial design for its deuterated DMT candidate in generalized anxiety disorder after completing a Phase II signal-finding study earlier this year. New CEO Michael Halstead emphasized unmet need in both mental-health indications, but provided no efficacy, safety, or financial data.

Analysis

HELP is effectively a binary clinical-event equity rather than a fundamentals story: the upcoming pivotal readout will determine whether its serotonergic platform earns strategic value or requires recapitalization. The key underwriting issue is not simply statistical success, but whether efficacy is durable, tolerability supports repeat use, and the treatment protocol can be commercialized with materially less clinical supervision than legacy psychedelic-assisted approaches. A positive result without a credible low-burden administration model may create a short-lived relief rally but leave peak-sales assumptions constrained by provider capacity and reimbursement friction.

Near term, management-transition risk is underappreciated. A newly installed CEO can improve investor messaging and trial-readout preparation, but also raises the probability of a post-data portfolio reset, financing, or revised development sequencing if results are equivocal. Over the next 1-3 months, monitor cash runway, enrollment/data-lock confirmation, and the prespecified endpoint and multiplicity framework; these matter more than conference commentary. In a positive-data scenario, Compass Pathways (CMPS) and ATAI Life Sciences (ATAI) may rerate through read-across, while their own differentiated protocols and timelines mean the sympathy move should be treated as a liquidity trade, not validation.

Consensus appears prone to value a successful readout as a direct proxy for approval and large-scale MDD penetration. The more relevant 6-18 month question is comparative positioning versus generic antidepressant augmentation, Spravato, and emerging neuropsychiatric assets: payer acceptance will require compelling durability and a favorable resource-use profile. Conversely, because the stock likely embeds substantial failure risk, a clean efficacy and safety outcome could produce a disproportionate multiple expansion before commercialization details become the limiting debate.

Key Decisions for Investors

• Do not establish a core directional position in HELP solely from this presentation; wait for independently verifiable confirmation of pivotal-study timing, endpoints, sample size, cash runway, and expected data-release window. Treat any delay in data lock or material change in endpoint framing as thesis-negative.
• For event-risk capital, consider a small, predefined-risk long HELP position only after data timing is formally reconfirmed; size it as a binary biotech exposure, with a loss assumption approaching the full premium/capital at risk rather than a conventional stop-loss framework.
• Use CMPS and ATAI as a post-readout basket trade rather than preemptive longs: buy a limited sympathy position only following clearly positive HELP data and exit within days to weeks unless company-specific catalysts validate the move. Their read-through is strongest on evidence that supervised serotonergic therapy can show durable benefit with manageable safety.
• If HELP rallies materially ahead of the readout without disclosed cash-runway improvement or protocol-economics evidence, reduce exposure or express a cautious relative-value stance via long XBI versus HELP. The falsifier is a clean pivotal result paired with explicit durable efficacy and a commercially scalable treatment workflow.
• Set alerts for financing disclosures and guidance around the follow-on anxiety program. A dilutive raise before pivotal data, or a materially more resource-intensive next-study design than anticipated, would weaken upside asymmetry even if the lead program remains on schedule.